- Home
- IMUX vs INMB Comparison
IMUX vs INMB Comparison
Compare IMUX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- INMB
- Stock Information
- Founded
- IMUX 2016
- INMB 2015
- Country
- IMUX United States
- INMB United States
- Employees
- IMUX N/A
- INMB N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- INMB Health Care
- Exchange
- IMUX Nasdaq
- INMB Nasdaq
- Market Cap
- IMUX 67.8M
- INMB 68.9M
- IPO Year
- IMUX N/A
- INMB 2019
- Fundamental
- Price
- IMUX $0.96
- INMB $2.68
- Analyst Decision
- IMUX Strong Buy
- INMB Buy
- Analyst Count
- IMUX 5
- INMB 4
- Target Price
- IMUX $7.50
- INMB $9.53
- AVG Volume (30 Days)
- IMUX 1.1M
- INMB 2.7M
- Earning Date
- IMUX 08-11-2025
- INMB 08-04-2025
- Dividend Yield
- IMUX N/A
- INMB N/A
- EPS Growth
- IMUX N/A
- INMB N/A
- EPS
- IMUX N/A
- INMB N/A
- Revenue
- IMUX N/A
- INMB $50,000.00
- Revenue This Year
- IMUX N/A
- INMB $203.60
- Revenue Next Year
- IMUX N/A
- INMB $13,122.47
- P/E Ratio
- IMUX N/A
- INMB N/A
- Revenue Growth
- IMUX N/A
- INMB N/A
- 52 Week Low
- IMUX $0.56
- INMB $1.89
- 52 Week High
- IMUX $2.11
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- IMUX 55.60
- INMB 39.52
- Support Level
- IMUX $0.94
- INMB $2.62
- Resistance Level
- IMUX $1.18
- INMB $3.24
- Average True Range (ATR)
- IMUX 0.08
- INMB 0.27
- MACD
- IMUX 0.01
- INMB 0.24
- Stochastic Oscillator
- IMUX 40.95
- INMB 53.16
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.